

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:
Abdolmohammed Rostami *et al.*

Application No.: 09/943,688

Group Art Unit: 1651

Filed: 08/31/2001

Examiner: M. Flood

RECEIVED

SEP 20 2002

TECH CENTER 1600/2900

Title: Use of Bowman Birk Inhibitor for the Treatment of MS and Other Autoimmune Diseases

Assistant Commissioner for Patents
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:


In response to the Restriction Requirement mailed August 19, 2002, Applicants elect to prosecute the subject matter of Group I, identified by Claims 1-13.

It is respectfully noted that Claims 14-19 (Group II) have been cancelled, without prejudice, and, therefore, are not pending in the above-identified application.

Should the Examiner have any questions or comments regarding Applicants' amendments or response, (s)he is asked to contact Applicants' undersigned representative at (215) 575-7034. Please direct all correspondence to the below-listed address.

If there are any fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0979.

Respectfully submitted,


Evelyn H. McConathy
Registration No. 35,279

Date: **September 17, 2002**
DILWORTH PAXSON LLP
3200 Mellon Bank Center
1735 Market Street
Philadelphia, PA 19103-7595
Tel. (215) 575-7000
Fax (215) 575-7200

466012_1

EL954913822US

Date Mailed: 09/17/02